Impact of metabolic syndrome on clinical outcomes after new generation drug-eluting stent implantation: The 'obesity paradox' phenomenon is still apparent

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 4, 2013, Pages 307-313

  Patsa, C ^a   Toutouzas, K ^a   Tsiamis, E ^a   Tsioufis, C ^a   Spanos, A ^b   Karanasos, A ^a   Michelongona, A ^a   Tousoulis, D ^a   Stefanadis, C ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

Metabolic syndrome; New generation drug eluting stent; Obesity

Indexed keywords

AGED; ARTICLE; BODY MASS; CHI SQUARE DISTRIBUTION; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; EQUIPMENT; FEMALE; GREECE; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TIME; TREATMENT OUTCOME;

AGED; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; GREECE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875080514     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.05.002     Document Type: Article

References (32)

1. Caixeta A., Leon M.B., Lansky A.J., Nikolsky E., Aoki J., Moses J.W., et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009 Sep 1, 54(10):894-902.
2. Ellis S.G., Stone G.W., Cox D.A., Hermiller J., O'Shaughnessy C., Mann T., et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009 Dec, 2(12):1248-1259.
3. Moussa I., Leon M.B., Baim D.S., O'Neill W.W., Popma J.J., Buchbinder M., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004 May 18, 109(19):2273-2278.
4. Carlsson J., von Wagenheim B., Linder R., Anwari T.M., Qvist J., Petersson I., et al. Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature. Clin Res Cardiol 2007 Feb, 96(2):86-93.
5. Gershlick A., Kandzari D.E., Leon M.B., Wijns W., Meredith I.T., Fajadet J., et al. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007 Oct 22, 100(8B):45M-55M.
6. Garg S., Serruys P.W., Miquel-Hebert K. Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial. Catheter Cardiovasc Interv 2010 Sep 7.
7. Solymoss B.C., Bourassa M.G., Campeau L., Sniderman A., Marcil M., Lesperance J., et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004 Jan 15, 93(2):159-164.
8. Farias D.R., Pereira A.F., Rosa G. Metabolic syndrome in coronary artery and occlusive vascular diseases: a systematic review. Arq Bras Cardiol 2010 Jun, 94(6):150-178.
9. Canibus P., Faloia E., Piva T., Mucai A., Serenelli M., Perna G.P., et al. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation. Metabolism 2008 May, 57(5):593-597.
10. Executive Summary of the Third report of the National cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III). JAMA 2001 May 16, 285(19):2486-2497.
11. Lean M.E., Han T.S., Morrison C.E. Waist circumference as a measure for indicating need for weight management. BMJ 1995 Jul 15, 311(6998):158-161.
12. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007 May 1, 115(17):2344-2351.
13. Mehran R., Dangas G., Abizaid A.S., Mintz G.S., Lansky A.J., Satler L.F., et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999 Nov 2, 100(18):1872-1878.
14. Mottillo S., Filion K.B., Genest J., Joseph L., Pilote L., Poirier P., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010 Sep 28, 56(14):1113-1132.
15. Dohi T., Miyauchi K., Kasai T., Kajimoto K., Kubota N., Tamura H., et al. Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J 2009 Aug, 73(8):1454-1458.
16. Lee M.G., Jeong M.H., Ahn Y., Chae S.C., Hur S.H., Hong T.J., et al. Impact of the metabolic syndrome on the clinical outcome of patients with acute ST-elevation myocardial infarction. J Korean Med Sci 2010 Oct, 25(10):1456-1461.
17. Rana J.S., Monraats P.S., Zwinderman A.H., de Maat M.P., Kastelein J.J., Doevendans P.A., et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care 2005 Apr, 28(4):873-877.
18. Kim J.S., Lee H.C., Choi B.K., Lee H.W., Park J.S., Lee Y.H., et al. Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation. Diabetes Res Clin Pract 2010 Jun, 88(3):e38-41.
19. Hoffmann R., Stellbrink E., Schroder J., Grawe A., Vogel G., Blindt R., et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am J Cardiol 2007 Nov 1, 100(9):1347-1352.
20. Sarno G., Garg S., Onuma Y., Buszman P., Linke A., Ischinger T., et al. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). Am J Cardiol 2010 Feb 15, 105(4):475-479.
21. Lancefield T., Clark D.J., Andrianopoulos N., Brennan A.L., Reid C.M., Johns J., et al. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv 2010 Jun, 3(6):660-668.
22. Minutello R.M., Chou E.T., Hong M.K., Bergman G., Parikh M., Iacovone F., et al. Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry). Am J Cardiol 2004 May 15, 93(10):1229-1232.
23. Kang W.Y., Jeong M.H., Ahn Y.K., Kim J.H., Chae S.C., Kim Y.J., et al. Obesity paradox in Korean patients undergoing primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. J Cardiol 2010 Jan, 55(1):84-91.
24. Nikolsky E., Kosinski E., Mishkel G.J., Kimmelstiel C., McGarry T.F., Mehran R., et al. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol 2005 Mar 15, 95(6):709-715.
25. Feher G., Koltai K., Alkonyi B., Papp E., Keszthelyi Z., Kesmarky G., et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol 2007 Aug 21, 120(2):188-192.
26. Tamminen M., Lassila R., Westerbacka J., Vehkavaara S., Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003 Aug, 27(8):907-911.
27. Wang Z.J., Zhou Y.J., Liu Y.Y., Yu M., Shi D.M., Zhao Y.X., et al. Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents. Heart 2009 Oct, 95(19):1587-1592.
28. Geisler T., Langer H., Wydymus M., Gohring K., Zurn C., Bigalke B., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006 Oct, 27(20):2420-2425.
29. West N.E., Ruygrok P.N., Disco C.M., Webster M.W., Lindeboom W.K., O'Neill W.W., et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004 Feb 24, 109(7):867-873.
30. Kornowski R., Mintz G.S., Kent K.M., Pichard A.D., Satler L.F., Bucher T.A., et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997 Mar 18, 95(6):1366-1369.
31. Fajadet J., Wijns W., Laarman G.J., Kuck K.H., Ormiston J., Baldus S., et al. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. EuroIntervention 2010 Nov, 6(5):562-567.
32. Jimenez-Quevedo P., Sabate M., Angiolillo D.J., Costa M.A., Alfonso F., Gomez-Hospital J.A., et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006 Jun 6, 47(11):2172-2179.